These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20520293)

  • 21. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME; Macfadden W; Weisler RH; Chang W; Paulsson B; Khan A; Calabrese JR;
    J Clin Psychopharmacol; 2006 Dec; 26(6):600-9. PubMed ID: 17110817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early response and 8-week treatment outcome in GAD.
    Rynn M; Khalid-Khan S; Garcia-Espana JF; Etemad B; Rickels K
    Depress Anxiety; 2006; 23(8):461-5. PubMed ID: 16845651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
    Holman AJ; Myers RR
    Arthritis Rheum; 2005 Aug; 52(8):2495-505. PubMed ID: 16052595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
    Sramek JJ; Tansman M; Suri A; Hornig-Rohan M; Amsterdam JD; Stahl SM; Weisler RH; Cutler NR
    J Clin Psychiatry; 1996 Jul; 57(7):287-91. PubMed ID: 8666569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
    Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
    Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder.
    DelBello MP; Chang K; Welge JA; Adler CM; Rana M; Howe M; Bryan H; Vogel D; Sampang S; Delgado SV; Sorter M; Strakowski SM
    Bipolar Disord; 2009 Aug; 11(5):483-93. PubMed ID: 19624387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.
    Vaishnavi S; Alamy S; Zhang W; Connor KM; Davidson JR
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1464-9. PubMed ID: 17698275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA; Vermani M; Jacobs L; Marcus M; Kong B; Lessard S; Galarraga W; Struzik L; Gendron A
    J Anxiety Disord; 2008 Dec; 22(8):1480-6. PubMed ID: 18455360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
    Citrome L
    Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
    Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
    Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of ziprasidone monotherapy in patients with anxious depression: a 12-week, randomized, double-blind, placebo-controlled, sequential-parallel comparison trial.
    Heo JY; Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; Pisoni A; Papakostas GI
    J Psychiatr Res; 2015 Mar; 62():56-61. PubMed ID: 25659187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychomotor symptoms and treatment outcomes of ziprasidone monotherapy in patients with major depressive disorder: a 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial.
    Jeon HJ; Fava M; Mischoulon D; Baer L; Clain A; Doorley J; DiPierro M; Cardoos A; Papakostas GI
    Int Clin Psychopharmacol; 2014 Nov; 29(6):332-8. PubMed ID: 24815673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of response to ziprasidone: results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state.
    Pae CU; Patkar AA; Gilmer W; Holtzman N; Thommi SB; Ghaemi SN
    Pharmacopsychiatry; 2012 Jun; 45(4):152-5. PubMed ID: 22294238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study.
    Pascual JC; Soler J; Puigdemont D; Pérez-Egea R; Tiana T; Alvarez E; Pérez V
    J Clin Psychiatry; 2008 Apr; 69(4):603-8. PubMed ID: 18251623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.